NEEDHAM, Mass.--(BUSINESS WIRE)--AVANT Immunotherapeutics, Inc. (NASDAQ: AVAN) and Select Vaccines Limited (ASX: SLT), an Australian biotechnology company, today announced a research and development (R&D) partnership focused on the use of Select Vaccines’ virus-like particles (VLPs) as a platform technology for the development of viral vaccines. The R&D efforts will initially target the development of vaccines against influenza including both epidemic and pandemic forms of vaccine, with the opportunity to expand the collaboration to other disease targets. In preclinical studies, Select Vaccines has demonstrated proof-of-principle for expressing vaccine antigens on Select VLPs with approximately 10 different antigens. Completion of the partnership agreement is subject to the approval of Select’s shareholders.
